(Q37831801)

24 August 2017

1 reference

title

The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling (English)

1 reference

24 August 2017

W van Veelen

1

1 reference

24 August 2017

S E Korsse

series ordinal

2

1 reference

24 August 2017

L van de Laar

series ordinal

3

1 reference

24 August 2017

M P Peppelenbosch

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

24 January 2011

1 reference

24 August 2017

1 reference

24 August 2017

30

1 reference

24 August 2017

20

1 reference

24 August 2017

2289-2303

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2010.630

24 August 2017

0 references

cites work

LKB1-dependent signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

mTOR cascade activation distinguishes tubers from focal cortical dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

21 January 2018

The two TORCs and Akt.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Comprehensive proteomic analysis of human Par protein complexes reveals an interconnected protein network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Hamartomatous polyposis syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Identification and characterization of the tuberous sclerosis gene on chromosome 16

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The Eker rat: establishing a genetic paradigm linking renal cell carcinoma and uterine leiomyoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Mammalian TOR: a homeostatic ATP sensor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

STRADalpha regulates LKB1 localization by blocking access to importin-alpha, and by association with Crm1 and exportin-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Tuberous sclerosis complex: a brave new world?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

AMPK phosphorylation of raptor mediates a metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Novel mechanism of regulation of the DNA repair enzyme OGG1 in tuberin-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

A serine/threonine kinase gene defective in Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

LKB1; linking cell structure and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycins: mechanism of action and cellular resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Signaling by target of rapamycin proteins in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

TORC1 is essential for NF1-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Fibroblasts from normal skin of a tuberous sclerosis patient show upregulation of mTOR pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Hedgehog signalling in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Expanding role of AMPK in endocrinology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Sirolimus and tuberous sclerosis-associated renal angiomyolipomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin: an anti-cancer immunosuppressant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

AMPK as a mediator of hormonal signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The role of leukotriene receptor signaling in inflammation and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Peutz-Jeghers syndrome: clinicopathology and molecular alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

mTORC1 directly phosphorylates and regulates human MAF1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Evidence that AMP triggers phosphorylation as well as direct allosteric activation of rat liver AMP-activated protein kinase. A sensitive mechanism to protect the cell against ATP depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin reduces seizure frequency in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Metformin activates AMP kinase through inhibition of AMP deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Metformin and cancer: licence to heal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Neurofibroma development in NF1--insights into tumour initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Lkb1 deficiency causes prostate neoplasia in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Tuberous sclerosis complex: advances in diagnosis, genetics, and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Regulation of mTOR and cell growth in response to energy stress by REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

21 January 2018

Peutz-Jeghers syndrome

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Suppression of B cell activation by cyclosporin A, FK506 and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Lessons from the Eker rat model: from cage to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

LKB1--a master tumour suppressor of the small intestine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Combined nephrectomy and pre-emptive renal transplantation in a tuberous sclerosis patient with angiomyolipoma, renal carcinoma and life-threatening abdominal haemorrhages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

5'-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.630

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.630

1 reference

Dimensions Publication ID

24 August 2017

0 references

1 reference